insurer glp-1 coverage news Costly Drugs are Rarely Covered for Weight Loss by Marketplace Plans Costly GLP-1 Drugs are Rarely

Depression is a highly prevalent mood disorder and one of the major health concerns in modern society

list price as of April 2026 (Novo Nordisk published pricing)

With key GLP-1 drug patents expected to expire around March 2026, Indian pharmaceutical companies are preparing to launch lower-cost alternatives in one of the fastest-growing therapeutic markets

Each capsule supports a healthy gut and promotes metabolic health for a balanced lifestyle

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand

A recent study shows that metabolic surgery delivers more effective and durable obesity outcomes than GLP-1 therapy, where real-world discontinuation exceeds 5070%